From 9th to 10th December 2023, The 3rd National Pediatric Functional Neurosurgery Workshop and The 10th TSC-related Epilepsy and Epileptic Encephalopathy Surgical Treatment Seminar were held in Beijing China Palace Hotel, sponsored by the National Children's Medical Center and the Beijing Children's Hospital affiliated to Capital Medical University, and co-sponsored by the Beijing Anti-epilepsy Association.

    Keanrui Pharmaceutical Group which is a general agent of Xianluoli ® Sirolimus Gel for tuberous sclerosis angiofibroma in China held a launch conference for the first targeted drug in the world. .

(Left to right: Mr. Jiang Rongzhe, General Manager of Jiangsu NobelPharma Pharmaceutical Co., Ltd., Mr. SHIOMURA, Managing Director&CEO of Nobelpharma Co., Ltd., Mr. Li Chao, President of Keanrui Pharmaceutical Group, and Mr. Liu Jinzhu, Head of Beijing Bowtie tuberous sclerosis Complex Rare Disease Care Center)

    Xianluoli® Sirolimus Gel is developed and manufactured by Nobelpharma, a pharmaceutical company founded in 2003 and headquartered in Tokyo, Japan. Based on the mission of "contributing to society by providing needed but neglected medicines and medical devices", Nobelpharma has obtained approval for 16 new drugs, 6 expanded indications, and 1 new medical device, etc. Among them, 15 products are designated as rare disease treatment products, and 2 products including Sirolimus Gel are recognized as "priority review" by Japan.

    Xianluoli® Sirolimus Gel is the first globally verified drug for the clinical efficacy of angiofibromas in tuberous sclerosis complex, and also the only mTOR inhibitor that can be administered facially to avoid systemic adverse reactions, making it more tolerable for patients.

    Xianluoli® Sirolimus Gel was approved for sale in China on March 28 this year. At present, the product has completed production, import, customs clearance and drug testing processes, and is now available to Chinese patients. This brings light to patients suffering from facial angiofibromas caused by TSC, who wander like walking in the dark. After treatment with Sirolimus Gel, these patients can go to school, find a job, fall in love, and live a healthy and happy life.

    Mr. Li Chao, President of Keanrui Pharmaceutical Group, Mr. SHIOMURA, President of Nobelpharma Pharmaceutical Co., Ltd. and Mr. Liu Jinzhu, Head of Beijing Bowknot TSC Rare Disease Care Center attended the conference and delivered speeches.

    Professor Xu Zigang from Beijing Children's Hospital and Professor Kenji Shimizu from Japan talked about the treatment progress of TSC-related skin diseases and the development and the research of Xianluoli® sirolimus gel in the treatment of facial fibrohemangioma was shared by them. 

    After more than 20 years of development, Keanrui Pharmaceutical Group currently has three production bases in Nanjing, Yunnan and Tianjin, as well as two health industrial parks in Beijing and Nanjing. Its products cover multiple clinical treatment fields. In the future, Keanrui will strive to reduce the burden on patients while providing more therapeutic drugs for rare disease patients.